Risk factors associated with symptoms of temporomandibular disorders among women with hypermobile Ehlers–Danlos syndrome: Questionnaire‐based study in Finland and Sweden
Journal of Oral Rehabilitation · 2024
DOI: 10.1111/joor.13706 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oral Rehabilitation, 2024. Verfasst von Negin Yekkalam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Odontology, Clinical Oral Physiology, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Temporomandibular Joint Disorders, Ehlers-Danlos Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Generalized joint hypermobility as a characteristic feature of Ehlers–Danlos syndromes (EDS) is among the factors contributing to temporomandibular disorders (TMD).
Objective
To evaluate the prevalence of TMD symptoms and their risk factors among women born in Sweden or Finland who were 27‐ to 78‐year‐olds with diagnosed hypermobile EDS (hEDS).
Methods
A cohort of women with confirmed hEDS ( n = 185) was constructed from the members of the National EDS Associations in both countries. Based on questionnaire data, frequency of independent variables in terms of socio‐demographic, general health and oral health‐related factors, comorbid symptoms and psychological distress for self‐reported TMD symptoms as the dependent variables, were calculated first. Prevalence ratios (PR) and their 95% confidence interval (95% CI) were estimated for the association between independent and dependent variables.
Results
Nearly all participants reported TMD symptoms (98%) with TMD pain (95%), TMJ clicking (90%) and jaw fatigue (80%) as the most common symptoms and TMJ crepitation (63%) and luxation (44%) as the least common symptoms. Risk factors for TMD among 27‐ to 50‐year‐olds participants were Finland as a country of birth, living alone and self‐reported worst pain in the body (not the joints). The respective risk factors among the 51‐ to 78‐year‐olds were Finland as a country of birth, family history of EDS, tinnitus and regularly taking contraceptives.
Conclusions
Among adult women with confirmed hEDS, socio‐demographic and health‐related factors and comorbid symptoms were significantly associated with TMD but with differences regarding age group. Therefore, management of TMD requires a multidisciplinary approach among the affected.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Odontology, Clinical Oral Physiology, Umeå University, Umeå, Sweden.
- Department of Community Medicine and Rehabilitation, Rehabilitation Medicine, Umeå University, Umeå, Sweden.
- Centre for Clinical Research, Västmanland Hospital, Uppsala University, Västerås, Sweden.
- Research Unit of Population Health, University of Oulu, Oulu, Finland.
- Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
ORCID-Profile: Negin Yekkalam, Mehmed Novo, Mårten J Tyrberg, Kirsi Sipilä
Zitieren
APA
Yekkalam, N., Novo, M., Tyrberg, M. J., & Sipilä, K. (2024). Risk factors associated with symptoms of temporomandibular disorders among women with hypermobile Ehlers–Danlos syndrome: Questionnaire‐based study in Finland and Sweden. Journal of Oral Rehabilitation. https://doi.org/10.1111/joor.13706
Vancouver
Yekkalam N, Novo M, Tyrberg MJ, Sipilä K. Risk factors associated with symptoms of temporomandibular disorders among women with hypermobile Ehlers–Danlos syndrome: Questionnaire‐based study in Finland and Sweden. Journal of Oral Rehabilitation. 2024. doi:10.1111/joor.13706
BibTeX
@article{Yekkalam2024,
author = {Yekkalam, Negin and Novo, Mehmed and Tyrberg, Mårten J and Sipilä, Kirsi},
title = {Risk factors associated with symptoms of temporomandibular disorders among women with hypermobile Ehlers–Danlos syndrome: Questionnaire‐based study in Finland and Sweden},
journal = {Journal of Oral Rehabilitation},
year = {2024},
doi = {10.1111/joor.13706}
}
EUVIMED